This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
This is an observational, retrospective and prospective study where subjects who have received mogamulizumab either within one year before or within 18 months after transplantation will be followed for data collection. Data will be collected at baseline (retrospectively), 100 days post alloHCT, 6-months, 1 year and at 2 years post alloHCT (retrospectively and prospectively). A cut-off time limit of 18 months post alloHCT exposure will allow at least 6 months of follow-up within the 2 years post-alloHCT follow-up period.
Study Type
OBSERVATIONAL
Enrollment
150
CIBMTR
Milwaukee, Wisconsin, United States
RECRUITINGAssess toxicities or complications of transplant among patients who were treated with mogamulizumab, alone or in combination
This study will utilize comprehensive report form (CRF) data, modified transplant essential data (TED) and supplemental data. In patients with only TED data the supplemental data will provide the required additional information for data analyses to meet the objectives of the study.
Time frame: one year prior to alloHCT to within 18 months after alloHCT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.